Exploring mechanisms of acquired taxane resistance in breast cancer
View/ Open
Date
16/08/2022Author
Taylor, Karen
Metadata
Abstract
Breast cancer is the most commonly diagnosed cancer globally and, despite advances
in detection and improved treatment, it remains the leading cause of cancer death
among women. Chemotherapy regimens include taxanes in combination, or in
sequence, with anthracyclines as first-line treatment with proven survival benefits.
However, the development of chemoresistance is a major clinical challenge in the
treatment of breast cancer with limited treatment options available thereafter.
Identification of mechanisms driving taxane resistance is therefore critical to
developing new treatment strategies to improve patient survival. The primary aim of
this thesis was to model acquired taxane resistance and identify actionable pathways
associated with the progression to a chemoresistant phenotype.
Isogenic models of acquired taxane resistance were developed from the breast
cancer cell lines MDA-MB-231 and MCF7 by continuous exposure to either paclitaxel
or docetaxel. STR profiling confirmed the parental lineage of the derived taxane
resistant isogenic cell lines and assessment of biomarkers by western blotting
confirmed retention of the triple negative phenotype of MDA-MB-231. MCF7 25PACR
cells exhibited a slight decrease in ERα expression but otherwise retained the protein
expression profile of its parent. The resistant cell lines exhibited the ability to
proliferate and progress through the cell cycle in the presence of taxanes, unlike the
parental cell lines which arrested at the G2/M phase. This was reflected in the
absence of apoptosis in the resistant cell lines when exposed to concentrations of
taxanes which induced cell death in the parental counterpart. Low level cross
resistance was observed to anthracyclines and other commonly used
chemotherapeutic agents. Expression of p-gyp protein encoded by MDR1 was
assessed by western blotting and shown to be slightly elevated in both MCF7 25PACR
and MDA-MB-231 25DOCR cell lines. However knockdown of MDR1 by siRNA did not
result in reversion to the same level of taxane sensitivity as observed in the parental
cell lines, suggesting other mechanisms are involved in the resistance observed in the
isogenic cell lines derived for this study.
To gain insight in to the pathways driving taxane resistance in the cell line models, a
multi-omic approach was taken. Targeted exome sequencing of the isogenic taxane
resistant cell lines revealed few resistance-associated genomic changes.
Transcriptomic analysis of the parental and isogenic taxane resistant cell lies was
performed by Nanostring®. Bioinformatic analysis revealed deregulation of the PI3-
Akt, MAPK, and transcriptional regulation pathways in the isogenic cell lines,
suggesting that inhibition of these pathways may be an effective treatment strategy
for taxane resistant breast cancer. RPPA and Western blotting confirmed these
findings and a small molecule kinase screen identified several clinically relevant
inhibitors with nanomolar potency in the resistant cell line models. The PI3K
inhibitors, PIK75 and BKM120, and the CDK inhibitors, dinaciclib and alvocidib, were
selected for further investigation via a combination of in vitro techniques.
Confirmation of their potency against all taxane resistant cell line models was
established and combination assays to assess synergy with other chemotherapeutics
performed.
Together, these results extend our knowledge of the drivers of taxane resistance in
breast cancer and support the use of PI3K and CDK inhibition as candidate
therapeutics in taxane resistant breast cancer.